Tuesday, June 12, 2012

Clinical trial-Hepatitis C Genotype 2 and 3 Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Sponsor: Bristol-Myers Squibb
Information provided by (Responsible Party):Bristol-Myers Squibb
ClinicalTrials.gov Identifier:NCT01616524

This study is not yet open for participant recruitment.
Verified June 2012 by Bristol-Myers Squibb   

First Received on June 7, 2012. No Changes Posted     
Estimated Enrollment:875
Study Start Date:July 2012
Purpose
The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and Daclatasvir will be safe and effective for treatment of hepatitis C compared to 24 weeks of treatment with Pegylated Interferon Alfa-2a plus Ribavirin
Posted by at
File Under

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)